<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">Remdesivir is a nucleotide analog and was effective against SARS-CoV, MERS-CoV, and bat CoV strains [
 <xref ref-type="bibr" rid="CR105">105</xref>]. Grein et al. reported clinical improvement in 36 (68%) out of 53 patients with severe COVID-19 who received at least one dose of remdesivir [
 <xref ref-type="bibr" rid="CR106">106</xref>]. And, the mortality rate in this group was lower than the general mortality rate in severe COVID-19 (13% versus &gt; 50%, respectively). However, in a recent, randomized, double-blind, placebo-controlled study (158 patients in remdesivir group versus 79 in the placebo group), Wang et al. reported that remdesivir was not associated with statistically significant clinical benefits although adequately tolerated by the patients [
 <xref ref-type="bibr" rid="CR107">107</xref>]. There are ongoing clinical trials on remdesivir use in COVID-19 (e.g., NCT04280705, NCT04315948).
</p>
